Recent News

• 11.05.2026 - Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance
• 10.29.2026 - Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts
• 10.22.2026 - Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026
• 10.21.2026 - Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses
• 10.06.2026 - Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life
• 09.08.2026 - Collegium to Participate in Upcoming Investor Conferences
• 08.13.2026 - Collegium Announces $50 Million Accelerated Share Repurchase Program
• 07.23.2026 - Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
• 07.20.2026 - Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
• 06.05.2026 - Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 10.30.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.29.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.19.2026 - 8-K Current report
• 10.08.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 09.30.2026 - 144 Report of proposed sale of securities
• 08.24.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.14.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.13.2026 - 8-K Current report
• 08.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.06.2026 - 8-K Current report